The most common adverse events include transient hypocalcemia, transient hypophosphatemia, and GI symptoms (e.g., abdominal pain, heartburn, nausea, constipation, diarrhea, flatulence, and esophagitis). Additional adverse events are myalgia, joint pain, headache, dizziness, peripheral edema, back pain, and weakness.

Rare but reported adverse events include toxic epidermal necrosis and oropharyngeal ulceration.

Post-marketing reports include rare occurrences of osteonecrosis of the jaw, generally associated with tooth extraction or local infection with delayed healing; esophageal erosions/esophagitis/esophageal ulcers; and hypersensitivity reactions.

Papamitsou T. et al. researched the effects of alendronate treatment on Wistar ratâ€™s stomach and liver.

Bautista-Villanueva S. et al. report on a patient who developed pustular skin reactions on both calves because of alendronate therapy.

Zhang C. et al. examined the effects of alendronate treatment on bone healing in ovariectomized 3-month-old female rats.

Naganathar N. et al. conducted a retrospective clinical study of the effects of alendronate therapy on renal function in patients (with osteoporosis, age > 65 years old) with decreased renal function (creatinine clearance < 35 ml/min).